Janssen Pharmaceuticals (J&J) Receives Health Canada’s Approval for Invokana (canagliflozin) in MACE Reduction

 Janssen Pharmaceuticals (J&J) Receives Health Canada’s Approval for Invokana (canagliflozin) in MACE Reduction

Janssen Pharmaceuticals (J&J) Receives Health Canada’s Approval for Invokana (canagliflozin) in MACE Reduction

Shots:

  • The approval is based on the CANVAS program i.e. CANVAS & CANVAS-R study assessing Invokana vs PBO in 10,142 adults with T2D who have or are at risk of CV diseases
  • CANVAS program results: combined MACE reduction 14% on separate bases (13%, 15% & 10%); 33% reduction in hospitalization & 30% reduction in death or hospitalization due to heart failure; mean fall in eGFR; risk of amputation ((0.59,0.75)/100 vs (0.28,0.42)/100) patient-years
  • Invokana is an PO qd SGLT2i, indicated for lowering blood glucose (sugar) levels in adults with T2D and is approved by Health Canada as monotx or + antihyperglycemic agents for improving glycemic control in adult patients T2D mellitus

Click here to read full press release/ article | Ref: PRNewswire| Image: RTE

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post